Induction Chemotherapy with or without Erlotinib in Patients with Head and Neck Squamous Cell Carcinoma Amenable for Surgical Resection

Overview of attention for article published in Clinical Cancer Research, April 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (84th percentile)
Above-average Attention Score compared to outputs of the same age and source (61st percentile)

So far, Altmetric has seen 10 X posts from 8 X users, with an upper bound of 9,716 followers.

局所進行口腔扁平上皮癌の臨床試験。プラチナ・タキサン系化学療法にエルロチニブを追加しても、高い効果は認められなかった。

RT @CCR_AACR: Phase 2 Study: Erlotinib chemotherapy neoadjuvant in HNSCC. https://t.co/gNYm5CFfMn https://t.co/4DcGwZbPaf

RT @CCR_AACR: Phase 2 Study: Erlotinib chemotherapy neoadjuvant in HNSCC. https://t.co/gNYm5CFfMn https://t.co/4DcGwZbPaf

Phase 2 Study: Erlotinib chemotherapy neoadjuvant in HNSCC. https://t.co/gNYm5CFfMn https://t.co/4DcGwZbPaf

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 6 additional X posts.